Rani Therapeutics (RANI) Competitors

Rani Therapeutics logo
$0.61 +0.05 (+9.40%)
As of 01:19 PM Eastern
This is a fair market value price provided by Massive. Learn more.

RANI vs. ALLO, FULC, EVMN, ALEC, and OCGN

Should you buy Rani Therapeutics stock or one of its competitors? Rani Therapeutics's main competitors and comparable companies include Allogene Therapeutics (ALLO), Fulcrum Therapeutics (FULC), Evommune (EVMN), Alector (ALEC), and Ocugen (OCGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Rani Therapeutics compare to Allogene Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.

Rani Therapeutics currently has a consensus price target of $8.33, indicating a potential upside of 1,389.69%. Allogene Therapeutics has a consensus price target of $8.30, indicating a potential upside of 1,015.44%. Given Rani Therapeutics' higher probable upside, equities research analysts plainly believe Rani Therapeutics is more favorable than Allogene Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rani Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Allogene Therapeutics
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.79

Rani Therapeutics has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.76, meaning that its share price is 24% less volatile than the broader market.

Allogene Therapeutics has a net margin of 0.00% compared to Rani Therapeutics' net margin of -493.00%. Allogene Therapeutics' return on equity of -49.84% beat Rani Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Rani Therapeutics-493.00% -76.64% -56.97%
Allogene Therapeutics N/A -49.84%-37.25%

30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Rani Therapeutics has higher revenue and earnings than Allogene Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rani Therapeutics$1.63M47.86-$29.67M-$0.19N/A
Allogene Therapeutics$20K12,890.42-$190.89M-$0.63N/A

In the previous week, Allogene Therapeutics had 1 more articles in the media than Rani Therapeutics. MarketBeat recorded 3 mentions for Allogene Therapeutics and 2 mentions for Rani Therapeutics. Allogene Therapeutics' average media sentiment score of 0.67 beat Rani Therapeutics' score of 0.50 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rani Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Allogene Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Allogene Therapeutics beats Rani Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Rani Therapeutics compare to Fulcrum Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and Fulcrum Therapeutics (NASDAQ:FULC) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

Rani Therapeutics has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, Fulcrum Therapeutics has a beta of 2.82, suggesting that its share price is 182% more volatile than the broader market.

Rani Therapeutics currently has a consensus target price of $8.33, indicating a potential upside of 1,389.69%. Fulcrum Therapeutics has a consensus target price of $8.20, indicating a potential upside of 118.67%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Rani Therapeutics is more favorable than Fulcrum Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rani Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Fulcrum Therapeutics
4 Sell rating(s)
7 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.75

Rani Therapeutics has higher earnings, but lower revenue than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rani Therapeutics$1.63M47.86-$29.67M-$0.19N/A
Fulcrum Therapeutics$80M3.58-$74.88M-$1.04N/A

In the previous week, Fulcrum Therapeutics had 4 more articles in the media than Rani Therapeutics. MarketBeat recorded 6 mentions for Fulcrum Therapeutics and 2 mentions for Rani Therapeutics. Rani Therapeutics' average media sentiment score of 0.50 beat Fulcrum Therapeutics' score of 0.48 indicating that Rani Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rani Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Fulcrum Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Fulcrum Therapeutics has a net margin of 0.00% compared to Rani Therapeutics' net margin of -493.00%. Fulcrum Therapeutics' return on equity of -19.94% beat Rani Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Rani Therapeutics-493.00% -76.64% -56.97%
Fulcrum Therapeutics N/A -19.94%-19.16%

30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 89.8% of Fulcrum Therapeutics shares are held by institutional investors. 26.7% of Rani Therapeutics shares are held by company insiders. Comparatively, 7.3% of Fulcrum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Rani Therapeutics beats Fulcrum Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Rani Therapeutics compare to Evommune?

Evommune (NYSE:EVMN) and Rani Therapeutics (NASDAQ:RANI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

Rani Therapeutics has lower revenue, but higher earnings than Evommune. Rani Therapeutics is trading at a lower price-to-earnings ratio than Evommune, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evommune$13M22.35-$68.87M-$3.81N/A
Rani Therapeutics$1.63M47.86-$29.67M-$0.19N/A

30.2% of Rani Therapeutics shares are owned by institutional investors. 31.1% of Evommune shares are owned by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Evommune had 15 more articles in the media than Rani Therapeutics. MarketBeat recorded 17 mentions for Evommune and 2 mentions for Rani Therapeutics. Evommune's average media sentiment score of 0.52 beat Rani Therapeutics' score of 0.50 indicating that Evommune is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Evommune
4 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Rani Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Evommune has a net margin of 0.00% compared to Rani Therapeutics' net margin of -493.00%. Evommune's return on equity of -43.53% beat Rani Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
EvommuneN/A -43.53% -40.11%
Rani Therapeutics -493.00%-76.64%-56.97%

Evommune currently has a consensus price target of $30.50, indicating a potential upside of 333.98%. Rani Therapeutics has a consensus price target of $8.33, indicating a potential upside of 1,389.69%. Given Rani Therapeutics' higher possible upside, analysts clearly believe Rani Therapeutics is more favorable than Evommune.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evommune
1 Sell rating(s)
4 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.69
Rani Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

Summary

Evommune beats Rani Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Rani Therapeutics compare to Alector?

Rani Therapeutics (NASDAQ:RANI) and Alector (NASDAQ:ALEC) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

Alector has a net margin of 23.87% compared to Rani Therapeutics' net margin of -493.00%. Alector's return on equity of 112.21% beat Rani Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Rani Therapeutics-493.00% -76.64% -56.97%
Alector 23.87%112.21%18.37%

Rani Therapeutics has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Alector has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market.

30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by insiders. Comparatively, 8.3% of Alector shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Rani Therapeutics has higher earnings, but lower revenue than Alector. Rani Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rani Therapeutics$1.63M47.86-$29.67M-$0.19N/A
Alector$21.05M18.11-$142.93M$0.357.31

In the previous week, Alector had 5 more articles in the media than Rani Therapeutics. MarketBeat recorded 7 mentions for Alector and 2 mentions for Rani Therapeutics. Alector's average media sentiment score of 1.05 beat Rani Therapeutics' score of 0.50 indicating that Alector is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rani Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Alector
1 Very Positive mention(s)
4 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Rani Therapeutics currently has a consensus price target of $8.33, suggesting a potential upside of 1,389.69%. Alector has a consensus price target of $5.10, suggesting a potential upside of 99.22%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Rani Therapeutics is more favorable than Alector.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rani Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Alector
2 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.43

Summary

Alector beats Rani Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Rani Therapeutics compare to Ocugen?

Rani Therapeutics (NASDAQ:RANI) and Ocugen (NASDAQ:OCGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership.

30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 10.3% of Ocugen shares are owned by institutional investors. 26.7% of Rani Therapeutics shares are owned by insiders. Comparatively, 4.0% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Ocugen had 3 more articles in the media than Rani Therapeutics. MarketBeat recorded 5 mentions for Ocugen and 2 mentions for Rani Therapeutics. Ocugen's average media sentiment score of 0.72 beat Rani Therapeutics' score of 0.50 indicating that Ocugen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Rani Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ocugen
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Rani Therapeutics currently has a consensus price target of $8.33, suggesting a potential upside of 1,389.69%. Ocugen has a consensus price target of $9.50, suggesting a potential upside of 1,155.45%. Given Rani Therapeutics' higher probable upside, analysts plainly believe Rani Therapeutics is more favorable than Ocugen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rani Therapeutics
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60
Ocugen
1 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.60

Rani Therapeutics has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Ocugen has a beta of 2.04, meaning that its share price is 104% more volatile than the broader market.

Rani Therapeutics has higher earnings, but lower revenue than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rani Therapeutics$1.63M47.86-$29.67M-$0.19N/A
Ocugen$4.41M58.22-$67.85M-$0.20N/A

Ocugen has a net margin of 0.00% compared to Rani Therapeutics' net margin of -493.00%. Rani Therapeutics' return on equity of -76.64% beat Ocugen's return on equity.

Company Net Margins Return on Equity Return on Assets
Rani Therapeutics-493.00% -76.64% -56.97%
Ocugen N/A -127,987.80%-98.50%

Summary

Rani Therapeutics beats Ocugen on 7 of the 13 factors compared between the two stocks.

Get Rani Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RANI and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RANI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RANI vs. The Competition

MetricRani TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$85.35M$4.00B$7.66B$11.73B
Dividend YieldN/A3.63%2.47%4.46%
P/E Ratio-3.2224.7134.0030.04
Price / Sales52.3615.848.445.70
Price / CashN/A22.9521.0121.90
Price / Book2.044.194.483.75
Net Income-$29.67M-$24.10M$3.51B$394.12M
7 Day Performance7.75%-7.66%-5.93%-5.63%
1 Month Performance-4.46%-5.73%-4.31%-6.93%
1 Year Performance-67.10%-6.16%-1.15%-7.12%

Rani Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RANI
Rani Therapeutics
1.7179 of 5 stars
$0.61
+9.4%
$8.33
+1,261.7%
-71.2%$85.35M$1.63MN/A69
ALLO
Allogene Therapeutics
3.1363 of 5 stars
$0.83
+0.7%
$8.30
+896.4%
-39.5%$291.73M$20KN/A152
FULC
Fulcrum Therapeutics
2.3587 of 5 stars
$3.79
+2.9%
$8.20
+116.6%
-61.1%$289.10M$80MN/A55
EVMN
Evommune
2.9528 of 5 stars
$7.95
-0.9%
$30.50
+283.9%
N/A$288.34M$10MN/A48
ALEC
Alector
4.6834 of 5 stars
$2.53
+3.1%
$5.10
+102.0%
+106.5%$282.17M$21.05M7.22103

Related Companies and Tools


This page (NASDAQ:RANI) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners